Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
DMARDs for Treating JIA (1 of 2)
Nonbiologic, synthetic DMARDs are small-molecule chemical drugs. The mechanism of action of each of these drugs is not well defined and is unknown in some cases.
Biologic DMARDs are genetically engineered antibodies and proteins that block the activity of immunostimulatory cytokines and other cell-signaling molecules. The tumor necrosis factor-alpha (TNF-α) blockers are the most typical members of this drug class. Other targets are interleukins 1 and 6 and the transmembrane proteins CD20 and CD28.
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | tumor necrosis factor-alpha | TNF-alpha | TNF-a
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.